Evidence map›Paper›PMID 39703189›Full record

ReviewCancer control : journal of the Moffitt Cancer Center

Research Hotspots and Trends of NK Cell Immunotherapy for Acute Myeloid Leukemia: A Bibliometric Analysis From 2000 to 2023.

Shupeng Chen, Jie Liu, Kaiyue Xia, Yao Gao, Yingjian Zeng

Abstract readReview
In one paragraph

Review in Cancer control : journal of the Moffitt Cancer Center. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Shupeng ChenSchool of Clinical Medicine, Jiangxi University of Chinese Medicine, Nanchang, China.ORCID 0009-0007-8064-4840
Jie LiuSchool of Clinical Medicine, Jiangxi University of Chinese Medicine, Nanchang, China.
Kaiyue XiaSchool of Clinical Medicine, Jiangxi University of Chinese Medicine, Nanchang, China.
Yao GaoSchool of Clinical Medicine, Jiangxi University of Chinese Medicine, Nanchang, China.
Yingjian ZengHematology Department, Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine, Nanchang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNatural killer (NK) cell immunotherapy has shown promising therapeutic potential for acute myeloid leukemia (AML), especially with advancements in chimeric antigen receptor-engineered NK cells (CAR-NK) and artificial intelligence (AI). Despite these developments, the field lacks comprehensive bibliometric analyses to identify research hotspots and trends, which could guide future precision treatments.

methodsA bibliometric analysis of NK cell immunotherapy for AML was conducted using literature from 2000 to 2023 retrieved from the Web of Science Core Collection database. Data visualization tools like CiteSpace, VOSviewer, and RStudio were employed to analyze publication trends, country contributions, institutional collaborations, influential authors, and research themes.

resultsThe analysis identified 1513 studies, with the United States and China leading global contributions. Notable institutions include the University of Minnesota and MD Anderson Cancer Center. Hot topics include allogeneic NK therapy, CAR-NK cell therapy, and memory-like NK cells. Emerging trends highlight the integration of intelligent NK cells and combinatory therapies, offering promising avenues for AML treatment. Despite progress, challenges such as NK cell expansion, activation, and resistance mechanisms remain critical areas for research.

conclusionThis study provides a comprehensive overview of the research landscape, highlighting the transformative potential of NK cell immunotherapy in AML. It underscores the need for international collaboration and continued innovation to overcome existing challenges and advance precision therapies.

Indexed as

BibliometricsKiller Cells, NaturalLeukemia, Myeloid, AcuteHumansImmunotherapyImmunotherapy, Adoptiveallogeneic NK cell therapyAMLbibliometricsCAR-NK cell therapyintelligentizationmemory-like NK cell therapyNK cells

Identifiers

PMID39703189
PMCPMC11660279

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.